For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
HOME > BUSINESS
BUSINESS
- Chugai Concludes Deal with Roche for Chugai’s Antibody Engineering Technologies
May 27, 2014
- Daiichi Sankyo, US Research Institute to Collaborate in Developing Cardiovascular-Metabolic Disease Treatments
May 26, 2014
- 3 More SGLT-2 Inhibitors Make Japan Debuts to Trail Suglat
May 26, 2014
- Astellas Launches Anticancer Drug Xtandi Capsules in Japan
May 26, 2014
- Three Companies Including DSP Jointly Invest 845 Million Yen in Create Vaccine
May 26, 2014
- Teikoku Seiyaku Licenses Antiallergic Treatment from Uriach of Spain
May 26, 2014
- Foreign Drug Makers’ Japan Units Underperform Market Growth in 2013
May 23, 2014
- Blopress AG Rollout Won’t Coincide with June Listing: ASKA Pres.
May 23, 2014
- 5 of 17 Pharmacy Chains Settle April-June Delivery Prices via Qol-Led Open Tender
May 23, 2014
- Teva Pharma Japan to Postpone NHI Price Listing of All Generics Including Valsartan in June
May 23, 2014
- JPMA Code Committee to Discuss Actions against Kyowa Kirin, Novartis over Improper Involvement in Clinical Trials
May 22, 2014
- Takeda’s UC, CD Treatment Entyvio Approved in US
May 22, 2014
- EPS Did Nothing Wrong in Data Verifications for VART Study Probe: Pres.
May 21, 2014
- AZ to Highlight Global Data to Push Forxiga: Primary Care Head
May 21, 2014
- Towa Wins Japan’s 1st Approval for Viagra Generic
May 21, 2014
- Improper Staffer Involvement in 4 More Japan CML Programs: Novartis
May 20, 2014
- Medipal Holdings Sets 2,253 Billion Yen Goal for FY2016 Ethical Drug Wholesaling Sales
May 20, 2014
- Daiichi Sankyo to Revise Its Midterm Business Plan Due to Transfer of Ranbaxy
May 20, 2014
- Sales of 25 Major Japan Drug Makers Up 10% as Top 4 Pharmas’ Offshore Revenues Flourish
May 19, 2014
- Blopress Generic to Go on Sale after June Listing, Japan’s 1st AG to Hit Shelves Before Rivals
May 19, 2014
ページ
Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…